 Dear Reader, Dr. Mark Skousen here. I've worked for the CIA. I've personally met four US presidents. I've spent 45 years studying the markets — calling Black Monday six weeks before it happened... predicting the fall of the Berlin Wall... pinpointing the exact bottom in 2009. But what I'm about to share with you is the boldest prediction of my career. After meeting Elon Musk face-to-face at a private gathering of Wall Street elites, I'm now staking my reputation on one date. March 26, 2026. Mark it on your calendar right now! That's when I believe Elon will announce the SpaceX IPO — what Bloomberg is calling "the biggest listing of ALL TIME." I have an "access code" that lets you grab a pre-IPO stake before it happens. But I'm only willing to share it with 500 people today. After that, you my never get the chance again. Click here to see how to claim your “SpaceX access code”. Yours for peace, prosperity, and liberty, AEIOU, Dr. Mark Skousen
Macroeconomic Strategist, The Oxford Club P.S. I don't make predictions lightly. When I put my name on something, I mean it. Click here before the 500 spots are gone.
Further Reading from MarketBeat Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsSubmitted by Nathan Reiff. Article Published: 3/12/2026. 
Key Points- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: You've Got to See This Pattern Before 2025 Picks Up… (From Stock Wire News)
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicines market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing therapies that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown substantial potential—and with that comes the possibility of significant sales. Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond offering potent treatment potential, these drugs could help the firms transition from unstable or penny-stock status toward greater stability and, potentially, long-term profitability. In both cases, significant challenges remain, making these typical biotech opportunities: high-risk investments that also have the potential to deliver outsized returns for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a HurdleIovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 slipped roughly 1%. That jump added to IOVA's strong year-to-date performance, which has more than doubled the stock's price so far. Still, with a consensus price target of $8.88, Wall Street expects further upside—about 71% from current levels, according to that target. The main catalyst for Iovance's rally is Amtagvi, a T-cell immunotherapy for certain forms of melanoma. Amtagvi was approved in the United States in 2024 and has been gaining momentum in sales and regulatory interest, with additional approvals possible in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Amtagvi's potential extends beyond melanoma: the drug received Fast Track Designation from the FDA for non–small cell lung cancer and may be effective against other tumor types as well. Some of Iovance's outperformance this year followed its Q4 2025 earnings report, issued in late February, in which the company reported smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year over year. Iovance is a relatively small biotech (around $2 billion in market value) and is often treated like a penny stock by some investors. Analysts remain cautious: about half of its roughly a dozen ratings are Hold or Sell. Risks are elevated—beyond the usual caveats for smaller biotech firms, Iovance's manufacturing model for Amtagvi is a vulnerability. The therapy is personalized, expensive, and complex to produce, which could constrain profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer DrugImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain optimistic: the average price target is $13.60, roughly 70% above the stock's current level even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the European regulator granted the drug conditional marketing authorization—the latest in a string of global approvals. Anktiva has been driving the company's revenue: it generated $113 million in sales last year, about a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional designations. Despite the dramatic share gains over recent quarters, IBRX remains speculative and risky. The company reported a full-year net loss of $351 million for 2025 as research-and-development expenses continued to mount. Wall Street analysts are comparatively bullish on ImmunityBio: six of seven coverage ratings currently recommend Buy or an equivalent. Both Iovance and ImmunityBio illustrate the classic biotech trade-off: compelling clinical and commercial potential paired with substantial execution and financial risks. For investors, these stocks may offer attractive upside, but they also carry the possibility of significant volatility and setbacks—appropriate only for those who understand and accept the risks.
This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to optout from receiving offers from The Oxford Club please click here | 
No comments:
Post a Comment